Table 4 Hematological neoplasm-related deaths differences between SSc patients and the general Spanish population by lineage
From: Neoplasm related mortality risk in Systemic Sclerosis: a nationwide study
Neoplasm-related deaths N (%) | OR (95% CI)* | |||
|---|---|---|---|---|
Non-SSc | SSc | p | ||
Hematological | 12,373 (8.9) | 5 (7.5) | 0.832 | 0.774 (0.310-1.928) |
Malign hemotological | 12,002 (8.6) | 5 (7.5) | 1 | 0.798 (0.320-1.989) |
Lymphoma | 4,245 (3) | 3 (4.5) | 0.460 | 1.379 (0.433-4.395) |
Hodgkin Lymphoma | 261 (0.2) | 0 | 1 | - |
Non-Hodgkin Lymphoma | 3,984 (2.9) | 3 (4.5) | 0.443 | 1.465 (0.460-4.668) |
B cell lineage | 3,545 (2.5) | 1 (1.5) | 1 | 0.534 (0.074-3.854) |
T/NK cell lineage | 439 (0.3) | 2 (3.0) | 0.019 | 8.955 (2.181-36.767) |
Leukemia | 4,630 (3.3) | 1 (1.5) | 0.728 | 1.940 (0.845-4.454) |
Myeloid lineage | 3,195 (2.3) | 0 | 0.410 | - |
Lymphoid lineage | 1,005 (0.7) | 1 (1.5) | 0.384 | 2.619 (0.641-0.585) |
Multiple myeloma | 2,165 (1.6) | 0 | 0.630 | - |
Myelodisplastic syndrome | 885 (0.6) | 1 (1.5) | 0.347 | 2.788 (0.384-20.240) |
Others | 77 (0.1) | 0 | 1 | - |
Unknown behavior | 371 (0,3) | 0 | 1 | - |
Myeloproliferative disorders | 243 (0.2) | 0 | 1 | - |
Others | 128 (0.1) | 0 | 1 | - |